Business Wire

CA-VELODYNE-LIDAR,-INC.

21.9.2021 10:02:09 CEST | Business Wire | Press release

Share
Velodyne Lidar Announces Multi-Year Supply Agreement with TOPODRONE

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced a multi-year agreement to provide its lidar sensors to TOPODRONE , which is based in Switzerland and develops affordable, high-precision solutions for aerial surveys. Using Velodyne lidar sensors has enabled TOPODRONE to bring high-precision mapping and 3D modeling to demanding environments including farms, forests, infrastructure and more to support development that advances economic and sustainability goals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005316/en/

Velodyne (Hall: 20, Booth: 20F.29) and TOPODRONE (Hall: 20, Booth: 20E.19) will showcase their lidar-based solutions for the geospatial community at INTERGEO 2021 , a world-leading expo and conference platform for geomatics and future-oriented solutions. The event takes place in Hannover, Germany on Sept. 21 to 23.

“Velodyne’s lidar sensors enable our solutions to capture intricate, precise measurements that are essential in producing a high-quality survey,” said Maxim Baklykov, Founder and CEO, TOPODRONE, a market leader in the survey sector. “The sensors’ light weight and compact form factor provide great synergy with one of TOPODRONE’s major principles of building some of the lightest lidar-based survey solutions in the market. Velodyne’s sensors provide best in class power consumption which allows drones to fly longer. Working with Velodyne has helped us leverage their well-known brand and product quality, which adds great value and customer confidence in our solutions.”

TOPODRONE is using Velodyne’s Puck™ , Puck Hi-Res™ and Ultra Puck™ as the 3D data perception and mapping sensors in its survey solutions . TOPODRONE 100 LITE and TOPODRONE 200 ULTRA are lightweight and accurate solutions that can be installed on drones, vertical take-off and landing (VTOL) unmanned aerial vehicles (UAVs) and backpack systems for mobile laser scanning. TOPODRONE 200 ULTRA, together with a Supercam SX350 VTOL, allows surveyors to cover more than 10 square kilometers per flight with high density and accurate RGB LiDAR point cloud data generated from 150 meters altitude.

TOPODRONE Delivers Precision Surveying for Customers Worldwide

TOPODRONE provides Velodyne lidar-powered scanner solutions to global markets with customers that include some of the world’s most renowned research universities. Researchers and specialists at the Natural Resources Institute Finland working on sustainable development of the Finnish bioeconomy used a TOPODRONE laser scanner mounted on a drone, quadbike and person. Even operating under hard winter conditions, such as flying under -20° C and during night, the scanner delivered high positional accuracy of collected point cloud data.

Another customer is Track Your Build, based in Sierra Leone, which offers remote sensing services for construction and infrastructure management. The company used a TOPODRONE scanner to conduct a successful topographical survey for a hydroelectric dam project. Track Your Build has now brought lidar-based surveying into its workflow for urban and rural areas to negate the need for spot elevations.

In Costa Rica, M. Eduardo Sáenz V, professional surveyor, uses TOPODRONE 100 LITE to survey forests, teak plantations, various types of farms and land for development. He commented, “The system has definitely made an impact, cutting costs and delivery times dramatically. It has proven reliable in tough working environments. The gain in time and detail are substantial. The possibilities for this tool are almost endless.”

“TOPODRONE has built an impressive global customer base by helping companies address a range of challenging mapping conditions and delivering accurate survey data,” said Erich Smidt, Vice President of Europe, Velodyne Lidar. “Their solutions demonstrate the performance and flexibility of Velodyne’s sensors by having a product family with multiple deployment modes.”

Velodyne’s lidar sensors make it quick and easy for companies to build highly accurate 3D models of any environment for mobile mapping. The sensors deliver a high-resolution, 360-degree surround view image to accurately measure and analyze the environment. The performance, range, light weight, low power consumption and compact form factor of Velodyne sensors enable developers to design versatile systems that can be configured for mobile and UAV/drone applications. Velodyne’s sensors have proven reliability, even when operating in difficult applications and weather conditions. To purchase Velodyne’s sensors, please contact Velodyne Sales at 669.275.2526, sales@velodyne.com .

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality, and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com .

Forward Looking Statements

This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, and competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include uncertainties regarding government regulation and adoption of lidar, the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. For more information about risks and uncertainties associated with Velodyne’s business, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of Velodyne’s SEC filings, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements in this press release are based on information available to Velodyne as of the date hereof, Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Link:

ClickThru

Social Media:

https://www.facebook.com/VelodyneLidar/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye